BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, January 4, 2026
See today's BioWorld Asia
Home
» Hatchtech Adds $7.8M, Preps for Phase III Trial of DeOvo
To read the full story,
subscribe
or
sign in
.
Hatchtech Adds $7.8M, Preps for Phase III Trial of DeOvo
May 16, 2012
By
Nuala Moran
LONDON – HatchTech Pty. Ltd. raised A$7.8 million (US$7.8 million) from existing investors, enabling it to push DeOvo, a metalloproteinase inhibitor for treating head lice, into a Phase III U.S. trial.
BioWorld Asia
